We close them. One compact team of scientists, strategists, operators and finance leads, carrying life-science and sustainability companies from the bench to the market.
The one-stop model
Ventures stall where the science meets the strategy, the regulator and the raise. We carry an idea across every one of those handovers: the same bench, the whole journey. You bring one objective, and we assemble the cross-functional team it actually needs (science, regulatory, commercial and finance) and nothing more.
Many specialisms in. One accountable team out.
Concept validation, freedom-to-operate and the scientific case behind the venture.
Fractional CTOs and product leads take the science from lab bench to a working, defensible platform.
Business-model validation, investment cases from grant funding to growth rounds, and warm introductions to capital.
Ideal-customer work, positioning and acquisition funnels that find and convert the right buyers.
Fractional chartered accountants, cash-flow forecasting and the KPIs boards and investors trust.
Three pillars
From the bench to a defensible platform, led by people who have built deep tech before: fractional CTOs, product leads and engineers who have carried their own science to market.
The commercial spine: a credible plan, a fundable story, and the introductions to back it, from business-model validation through to the close.
Demand and discipline: the right buyers found and converted, while the numbers stay board-ready behind them.
Who we work with
Seed-to-growth teams that need senior, part-time leadership across science, regulatory, commercial and finance, drawing on one bench instead of five separate firms.
External innovation, technology scouting and ESG programmes for established organisations, providing specialist firepower that plugs into your internal teams.
Technical and commercial due diligence on deep-tech assets, led by specialists who have founded, funded and run science companies of their own.
Specialist divisions
Life science Sustainability
Our deepest bench. We support drug and vaccine programmes from target validation through clinical strategy and regulatory submission, led by founders and scientists who have run real discovery programmes of their own.
Discuss a programmeBiosensors, diagnostics and functional materials: turning prototypes and concepts into reliable, scalable sensing and measurement systems, validated to the standard the market expects.
Discuss a programmeCommercialising nanomaterials and advanced polymers, from synthesis and characterisation to scale-up and route-to-market.
Discuss a programmeFrom first sketch to full market entry: proof-of-concept validation, product road-mapping and cost-of-goods optimisation, with fundraising and IP advice alongside.
Discuss a programmeClimate strategies, ESG frameworks and decarbonisation roadmaps for scaling ventures, corporates and policy bodies: credible, measurable and reportable.
Explore the sustainability practiceNew · Technology scouting
With our partner network we scout emerging technologies worldwide, connecting innovators expanding from India, Asia and China into the UK and Europe with the buyers, partners and capital that move them forward.
✓You’re on the list. The first brief lands soon.
A short brief, every couple of months, of the platforms we’re actively reviewing. No noise, easy unsubscribe.
Brief 01 · Diagnostics
Brief 02 · AI drug discovery
Brief 03 · Bioprocessing
Sustainability & ESG
Sustainability runs through everything we do, and stands alone for organisations that need a credible climate strategy: decarbonisation roadmaps, measurable targets and investor-grade reporting.
Explore the sustainability practiceThe network
Non-executive director
Polymer-chemistry and nanotechnology leader with 15 years converting molecular science into diagnostics; former Head of Chemistry at MIP Diagnostics; Cambridge Executive MBA.
Strategic finance
Senior international COO and finance executive with more than 20 years in strategic finance, monetisation and capital raising.
Financial leadership
Business strategist and fractional CFO with extensive international experience, helping SMEs, scale-ups and corporates build resilient, profitable businesses.
Operations & governance
Pharmaceutical operations leader experienced in translating global scientific programmes into governance and reliable delivery.
Regulatory affairs
Senior regulatory-affairs consultant with over 20 years in medical devices and IVD, guiding products to market across major jurisdictions.
Technology & IT
Group CIO and interim CISO leading enterprise digital transformation, cybersecurity and technology due diligence.
A boutique bench of fractional specialists: founders, academics and operators with verifiable track records, alongside a wider network across biotech, sensors, nanotechnology, venture acceleration and ESG.
Meet the entire networkTrack record across the network
Venture capital raised
~$25M
Raised by NanoSyrinx, the University of Warwick synthetic-biology spin-out founded by network member Joseph Healey, with backing from leading deep-tech investors.
Peer-reviewed papers
67+
Authored by Iva Chianella, a Cranfield sensor-development specialist on our bench, alongside book chapters and granted patents.
In drug discovery
25+ yrs
Brought by Parminder Ruprah, a Kuano co-founder and former Takeda group leader, across a career spent in drug discovery.
These are the verifiable public track records of individual network members: roughly $25M raised by NanoSyrinx, founded by Joseph Healey; 67+ peer-reviewed papers by Cranfield biosensor specialist Iva Chianella; and 25+ years in drug discovery from Parminder Ruprah, a Kuano co-founder and former Takeda group leader. They show the expertise CCP convenes in its people, not a guarantee of outcomes for any engagement.
Partner with us
We grow through people and partnerships: specialists who join the bench, and firms we co-deliver and exchange referrals with.
For specialists
Work fractional, founder-to-board mandates alongside senior peers, bringing your specialism, under the CCP banner, to the organisations that need exactly it.
For firms
Boutique consultancies, accelerators, investors and venture builders with an overlap to what we do: transparent, two-way agreements that grow both sides.
Open roles
Independent consultant and contractor roles. Send a CV and a line on what you’ve built.
Start the conversation
A free 30-minute discovery call, with no packages and no pitch theatre. We listen to your objective, then tell you honestly what it would take and who from the network should be in the room.
Book a free 30-minute call
